Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;9(1):160-162.
doi: 10.21037/tlcr.2019.11.14.

Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author's reply

Song-Tao Xu  1 , Jia-Cheng Yin  1 , Jun-Jie Xi  1 , Qun Wang  1 , Wen-Zhao Zhong  2 , Yi-Long Wu  2
Affiliations
Comment

Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author's reply

Song-Tao Xu et al. Transl Lung Cancer Res. 2020 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: WZZ serves as the unpaid Associate Editor-in-Chief of TLCR. YLW serves as the unpaid Honorary Editor-in-Chief of TLCR. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Xu ST, Xi JJ, Zhong WZ, et al. The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104). J Thorac Oncol 2019;14:503-12. 10.1016/j.jtho.2018.11.020 - DOI - PubMed
    1. Baba T, Uramoto H, Kuwata T, et al. Survival impact of node zone classification in resected pathological N2 non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2012;14:760-4. 10.1093/icvts/ivs058 - DOI - PMC - PubMed
    1. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-9. 10.1200/JCO.2000.18.16.2981 - DOI - PubMed
    1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-48. 10.1016/S1470-2045(17)30729-5 - DOI - PubMed
    1. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015;33:4007-14. 10.1200/JCO.2015.61.8918 - DOI - PubMed